Anthem Biosciences Ltd
Company Profile
Business description
Anthem Biosciences Ltd is mainly engaged in discovering, developing, manufacturing, and commercializing biopharmaceutical products that address unmet needs and provide biological solutions to improve industrial performance in all areas. The company offers its CRDMO services to biotech, pharmaceutical, and other companies for the development of large and small drug molecules, and also runs a products business offering specialty ingredients like fermentation products, peptides, lipids, probiotics, APIs, biosimilars, etc. Its reportable segments are: Contract Research Development and Manufacturing Services (CRDMO), which derives maximum revenue, and Specialty Ingredients. Geographically, the company generates maximum revenue from Europe, followed by North America, India, and other regions.
Contact
Phase 1, Canara Bank Road
No. 49, F1 and F2, Bommasandra Industrial Area
Bommasandra
BangaloreKA560099
INDT: +91 8066724000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
3,302
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,445.10 | 33.80 | 0.36% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,668.03 | 137.75 | 0.54% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 65,606.71 | 76.55 | -0.12% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,263.60 | 34.80 | 0.38% |
| SSE Composite Index | 3,940.04 | 39.68 | 1.02% |